• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Microbiol Spectr . Specific Detection of SARS-CoV-2 Variants B.1.1.7 (Alpha) and B.1.617.2 (Delta) Using a One-Step Quantitative PCR Assay

tetano

Editor, Senior Moderator
Microbiol Spectr


. 2022 Mar 14;e0217621.
doi: 10.1128/spectrum.02176-21. Online ahead of print.
Specific Detection of SARS-CoV-2 Variants B.1.1.7 (Alpha) and B.1.617.2 (Delta) Using a One-Step Quantitative PCR Assay


Oran Erster[SUP] 1 [/SUP], Ella Mendelson[SUP] 1 2 [/SUP], Areej Kabat[SUP] 1 [/SUP], Virginia Levy[SUP] 1 [/SUP], Batya Mannasse[SUP] 1 [/SUP], Hadar Assraf[SUP] 1 [/SUP], Roberto Azar[SUP] 1 [/SUP], Yaniv Ali[SUP] 1 [/SUP], Efrat Bucris[SUP] 1 [/SUP], Dana Bar-Ilan[SUP] 1 [/SUP], Orna Mor[SUP] 1 2 [/SUP], Michal Elul[SUP] 1 [/SUP], Michal Mandelboim[SUP] 1 2 [/SUP], Danit Sofer[SUP] 1 [/SUP], Shay Fleishon[SUP] 1 [/SUP], Neta S Zuckerman[SUP] #[/SUP][SUP] 1 [/SUP], Itay Bar-Or[SUP] #[/SUP][SUP] 1 [/SUP]



Affiliations

Abstract

In this report, we describe the development of a reverse transcription-quantitative PCR (RT-qPCR) assay, termed Alpha-Delta assay, which can detect all severe acute respiratory syndrome coronavirus 2 (SC-2) variants and distinguish between the Alpha (B.1.1.7) and Delta (B.1.617.2) variants. The Alpha- and Delta-specific reactions in the assay target mutations that are strongly linked to the target variant. The Alpha reaction targets the D3L substitution in the N gene, and the Delta reaction targets the spike gene 156 to 158 mutations. Additionally, we describe a second Delta-specific assay that we use as a confirmatory test for the Alpha-Delta assay that targets the 119 to 120 deletion in the Orf8 gene. Both reactions have similar sensitivities of 15 to 25 copies per reaction, similar to the sensitivity of commercial SC-2 detection tests. The Alpha-Delta assay and the Orf8[SUB]119del[/SUB] assay were successfully used to classify clinical samples that were subsequently analyzed by whole-genome sequencing. Lastly, the capability of the Alpha-Delta assay and Orf8[SUB]119del[/SUB] assay to identify correctly the presence of Delta RNA in wastewater samples was demonstrated. This study provides a rapid, sensitive, and cost-effective tool for detecting and classifying two worldwide dominant SC-2 variants. It also highlights the importance of a timely diagnostic response to the emergence of new SC-2 variants with significant consequences on global health. IMPORTANCE The new assays described herein enable rapid, straightforward, and cost-effective detection of severe acute respiratory syndrome coronavirus 2 (SC-2) with immediate classification of the examined sample as Alpha, Delta, non-Alpha, or non-Delta variant. This is highly important for two main reasons: (i) it provides the scientific and medical community with a novel diagnostic tool to rapidly detect and classify any SC-2 sample of interest as Alpha, Delta, or none and can be applied to both clinical and environmental samples, and (ii) it demonstrates how to respond to the emergence of new variants of concern by developing a variant-specific assay. Such assays should improve our preparedness and adjust the diagnostic capacity to serve clinical, epidemiological, and research needs.

Keywords: Alpha (B.1.1.7); Delta (B.1.617.2); RT-qPCR; SARS-COV-2; SC-2 surveillance; classification; diagnostic assay.
 
Back
Top Bottom